Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Cadexomer iodine; Fluorodeoxyglucose F18; Iodine

Criteria

Inclusion Criteria:- Patient at Nuclear Medicine clinic at Stanford University Medical Center

• Treated thyroid cancer.

• Detectable levels of Tg.

• Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.

• Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT

• Patients older than 18-year-old.

• Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.

• Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.

• Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them. Exclusion Criteria:- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.

• Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.

• Pregnant women.

• Healthy volunteers.

• Patients participating in other research studies.